Summary & Overview
CPT 82261: Biotinidase Enzyme Assay
CPT code 82261 represents a laboratory enzymatic assay to measure biotinidase activity, a diagnostic and confirmatory test for biotinidase deficiency. This test is clinically important for early identification and follow-up of affected individuals, particularly in newborn screening programs, because untreated deficiency can lead to neurologic and metabolic symptoms. Nationally, enzyme assays like 82261 are relevant to newborn screening workflows, metabolic clinics, and clinical laboratories that perform confirmatory testing.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, the clinical context for testing, and the typical settings where the service is provided. The publication also summarizes payer coverage patterns and benchmark considerations, highlights coding and billing implications relevant to laboratory services, and outlines clinical rationale for testing and follow-up. The content is intended to help laboratory managers, billing professionals, and clinical program leaders understand where 82261 fits into testing pathways and payer environments at a national level.
Billing Code Overview
CPT code 82261 describes a laboratory measurement of the enzyme biotinidase performed by a lab analyst, typically on a blood sample. The test identifies biotinidase deficiency and is used for follow-up testing after a previously positive newborn or screening result. Clinical features associated with biotinidase deficiency can include irritability, seizures, vomiting, and loss of appetite.
-
Service type: Laboratory enzymatic assay
-
Typical site of service: Clinical laboratory or hospital laboratory, with specimens commonly collected in outpatient clinics, newborn screening programs, or inpatient settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A newborn screening or outpatient metabolic evaluation patient presents after a positive newborn screen for biotinidase deficiency or with clinical signs such as unexplained seizures, feeding intolerance, hypotonia, or developmental delay. A clinician orders quantitative measurement of the enzyme biotinidase on a blood sample (usually serum or dried blood spot) to confirm deficiency. The clinical workflow includes specimen collection (venipuncture or heel stick), proper labeling and transport to a clinical laboratory, accessioning, and performance of the enzymatic assay by a laboratory technologist or clinical chemist. Results are reviewed by a pathologist or laboratory director and communicated to the ordering pediatrician, geneticist, or metabolic specialist for diagnostic confirmation, family counseling, and management decisions such as biotin supplementation and further genetic testing if indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the physician/pathologist interpretation component separate from the technical laboratory work. |
TC | Technical component | Use when billing only the laboratory technical component (equipment, reagents, technologist time). |